Further delays? Further pre-clinical studies required? Who knows.
If it was positive then there's nothing stopping PAR from announcing it as such. They could always include a caveat that they still require their regulatory consultants to go over the response and will update the market in due course about new timelines etc.
Alternatively, PAR did mention that they would re-evaluate the funding situation when the FDA approved the IND application. So they could be consulting with their regulatory consultants to ascertain the full impact of these new regulatory measures to timelines and costs etc.
Or did the FDA suggest something new that PAR should also monitor?
This is all speculation of course. If only those in the know could drop us a nugget like they did during the previous trading halt.
Good luck all.
Ann: Trading Halt, page-53
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $46.92K | 203.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 337 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |